Company intelligence / Profile preview

Albumedix

Nottingham, England, United Kingdomsartorius.com ↗

Ownership: Private
Employees: ~100
Development stage: Other

Overview

Albumedix provides best-in-class recombinant human albumin products that are USP-NF compliant. Their technologies support hundreds of millions of doses of clinical and marketed therapeutics worldwide. The company’s platforms enable improved stability, safety, and performance for advanced biopharmaceuticals including cell/gene/viral/protein-based therapies.

Therapeutic areas: Other
Modalities: Recombinant proteinProteinBiologic
Industry: Chemicals & Materials

Partnerships

Major partnerships with global biopharma companies using their recombinant albumin solutions; specifics not disclosed publicly.

Beyond the preview

Go deeper on Albumedix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Albumedix.

Explore the full profile